Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06993038

Adenosine vs Diltiazem for Treatment of SVT in the ED

This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Supraventricular Tachycardia (SVT) Arrhythmias, Cardiac Cardiac Conduction System Disease Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Tachycardia Tachycardia, Supraventricular

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University of Iowa Health Care

Iowa City, Iowa, 52242, United States

Location status: Recruiting

Location contact

Anne Zepeski, PhamD

CONTACT

[email protected]

651-207-9357

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients (18 years and older)
  • Diagnosis of acute, stable SVT in the emergency department

Exclusion criteria

  • Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting).
  • Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome
  • History of heart failure with reduce ejection fraction (HFrEF) (LVEF</= 40%)
  • Severe bronchoconstrictive lung disease
  • Prior hypersensitivity to study medication
  • Previously enrolled in pilot study
  • Pregnant
  • Incarcerated

Treatment and study plan

Adenosine

Drug

IV adenosine at standard doses for SVT (6 mg, 12 mg)

Diltiazem

Drug

IV diltiazem at standard doses for SVT (0.25 mg/kg)

Primary outcomes

  1. Feasibility outcome

    Time frame: From enrollment to the end of ED encounter (up to 24 hours).

    Patients with stable SVT are identified in the ED (Threshold >90%)

  2. Feasibility outcome

    Time frame: From enrollment to the end of ED encounter (up to 24 hours).

    Eligible participants who provide consent to participate (Threshold >50%)

  3. Feasibility outcome

    Time frame: From enrollment to the end of ED encounter (up to 24 hours).

    Participants who complete all study procedures (Threshold >80%)

Study contacts

Contact information is provided by the study sponsor or research team.

Anne Zepeski, PharmD

CONTACT

[email protected]

(319) 356-2577

Sponsors and collaborators

Lead sponsor

Anne E. Zepeski

Other

Registry information

Official study title

COMparison of Adenosine Versus Diltiazem FOR Supraventricular Tachycardia in the ED (COMFORT-ED) - Pilot Trial

Acronym: COMFORT-ED

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
May 28, 2025
Registry last updated
May 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.